Physician profile
Brian Bowlin
NPI 1548657406
$1,601.40
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $457 · 2021: $419 · 2022: $96.87 · 2023: $125 · 2024: $70.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $195.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $394.69 | 2019-2021 | |
| Novo Nordisk INC | $358.63 | 2019-2021 | |
| Abbott Laboratories | $315.71 | 2021-2024 | Freestyle Libre 3 |
| Pfizer INC. | $108.28 | 2019-2021 | |
| Amgen INC. | $71.68 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $57.54 | 2019-2020 | |
| Abbvie INC. | $56.28 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.07 | 2019-2023 | Jardiance |
| Allergan, INC. | $42.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.95 | 2021 | |
| Sobi, INC | $19.59 | 2019 | |
| Sanofi Pasteur INC. | $18.28 | 2019 | |
| Glaxosmithkline, LLC. | $15.74 | 2020 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.94 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $13.61 | 2020 | |
| Novartis Pharmaceuticals Corporation | $13.17 | 2019 | |
| Esperion Therapeutics, INC. | $12.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Bowlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.